Interestingly, IDH1/2 mutation was considerably prevalent (15/35; 43%) in our predominantly relapsed and refractory study population, in contrast to the 16–21% observed in recently published large series of newly diagnosed AML [38, 40]. This evidence concerns the gene IDH1 and acute myeloid leukemia.